MissionIR Articles

According to the National Institute of Mental Health (NIMH), major depression is one of the most common mental disorders in the United States. In 2013, an estimated 15.7 million individuals aged 18 or over –…

Millions of people around the world suffer from depression, which ranges from short-lived emotional responses to something as severe as suicide, positioning the mental disease as the leading cause of disability worldwide and a dire…

Unexpected cardiotoxicity, which damages the heart muscles, is among the most prevalent reasons for failure of both drugs and drug candidates. VistaGen Therapeutics, Inc. (OTCQB: VSTA), through its customized cellular assay system, CardioSafe 3D™, is…

VistaGen Therapeutics was founded in the late 1990s by a team of scientists believing that better cells lead to better medicine. In the years since, this California-based clinical-stage biopharmaceutical company also has focused on developing…

According to a report published in September of 2014 by Transparency Market Research on anxiety disorder and depression treatments, the global market for depression treatment was around $22.5 billion in 2013 and is estimated to…

If you think depression only affects the individual suffering from the disorder, or even their friends and family, think again. As a nation, depression affects all of us in one way or another. According to…

Ketamine has been shown as an extremely effective treatment for patients suffering from major depressive disorder (MDD). Unfortunately, its prospects for widespread therapeutic use are exceptionally limited because of its high potential for abuse, dissociative…

VistaGen Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative medicine for depression and conditions associated with the central nervous system, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National…

Believing that better cells lead to better medicine, VistaGen Therapeutics has been applying pluripotent stem cell technology toward drug rescue, predictive toxicology and drug metabolism screening. VistaGen’s activities are guided by the belief that the…

Since inception, VistaGen Therapeutics has focused on creating human cell-based biological assay systems that reveal the potential toxic effects of new drug candidates before they are tested in animals or humans. Today’s next-generation biological assays…

Depression, as many of us know, is more than just a sad or melancholy mood. It’s more than just having “the blues.” Sometimes it can be a very debilitating condition that can prevent people from…

VistaGen Therapeutics is bringing human biology to the front end of the long and costly drug development process. Among the most troubling aspects of drug development are unexpected heart and liver toxicities that often arise…

On the street ketamine is referred to as “Special K,” a drug popular in the party scene because of its hallucinogenic and other psychotomimetic, or psychosis-like, effects. In the operating room, ketamine has long been…

With the very public suicide of actor/comedian Robin Williams recently, the battle with major depressive disorder, or MDD, has moved even more into the public light. VistaGen Therapeutics, Inc. (OTCQB: VSTA) has become one of…

Depression affects nearly 7% of all adults in the U.S. and over 350M people worldwide according to the World Health Organization, and it is a major contributor to overall disease statistics. GBI Research forecasts the…

VistaGen signed a Letter of Intent to enter into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to collaborate on…

Potential to Address Major U.S. and Global Need It’s one of the single most sought-after drugs in the medical industry, and biotechnology company VistaGen Therapeutics may have it. What is so desperately needed is a…

Today before the opening bell, VistaGen Therapeutics announced its reception of a Notice of Allowance from the Canadian Intellectual Property Office. The Notice of Allowance enables further expansion of VistaGen Therapeutics’ intellectual property portfolio, which…

Last week, VistaGen Therapeutics implemented a 1-for-20 reverse split of its common stock. As a result, the number of shares of the company’s common stock outstanding was reduced from approximately 25.5 million to approximately 1.2…

In an 8-K filed with the SEC today, VistaGen Therapeutics announced that Platinum Long Term Growth VII, LLC, the company’s largest investor, has entered into an Amended and Restated Note Conversion Agreement and Warrant Amendment.…